Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Genomic Instability Associated with p53 Knockdown in the Generation of Huntington's Disease Human Induced Pluripotent Stem Cells.

Tidball AM, Neely MD, Chamberlin R, Aboud AA, Kumar KK, Han B, Bryan MR, Aschner M, Ess KC, Bowman AB.

PLoS One. 2016 Mar 16;11(3):e0150372. doi: 10.1371/journal.pone.0150372. eCollection 2016.

2.

Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.

Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H.

Mol Brain. 2012 May 21;5:17. doi: 10.1186/1756-6606-5-17.

3.

Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.

An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM.

Cell Stem Cell. 2012 Aug 3;11(2):253-63. doi: 10.1016/j.stem.2012.04.026. Epub 2012 Jun 28.

4.

Generation of induced pluripotent stem cell line, ICGi007-A, by reprogramming peripheral blood mononuclear cells from a patient with Huntington's disease.

Grigor'eva EV, Malankhanova TB, Surumbayeva A, Minina JM, Morozov VV, Abramycheva NY, Illarioshkin SN, Malakhova AA, Zakian SM.

Stem Cell Res. 2019 Jan;34:101382. doi: 10.1016/j.scr.2018.101382. Epub 2019 Jan 2.

5.

A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Tidball AM, Bryan MR, Uhouse MA, Kumar KK, Aboud AA, Feist JE, Ess KC, Neely MD, Aschner M, Bowman AB.

Hum Mol Genet. 2015 Apr 1;24(7):1929-44. doi: 10.1093/hmg/ddu609. Epub 2014 Dec 8.

6.

Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway.

Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M.

Dis Model Mech. 2015 Sep;8(9):1047-57. doi: 10.1242/dmm.019406. Epub 2015 Jun 18.

7.

Transient p53 suppression increases reprogramming of human fibroblasts without affecting apoptosis and DNA damage.

Rasmussen MA, Holst B, Tümer Z, Johnsen MG, Zhou S, Stummann TC, Hyttel P, Clausen C.

Stem Cell Reports. 2014 Sep 9;3(3):404-13. doi: 10.1016/j.stemcr.2014.07.006. Epub 2014 Aug 21.

8.

Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.

Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y, Lee DS, Seo KS, Choi NJ, Park BC, Kang SH, Ryu J, Oh SH, Shin DA, Lee DR, Do JT, Park IH, Daley GQ, Song J.

Biochem J. 2012 Sep 15;446(3):359-71. doi: 10.1042/BJ20111495.

PMID:
22694310
9.

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.

Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, Signer E, Kwak S, Marugan JJ, Botas J, Fischer DF, Svendsen CN, Munoz-Sanjuan I, Yang XW.

Sci Transl Med. 2014 Dec 24;6(268):268ra178. doi: 10.1126/scitranslmed.3010523.

PMID:
25540325
10.

Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.

HD iPSC Consortium.

Cell Stem Cell. 2012 Aug 3;11(2):264-78. doi: 10.1016/j.stem.2012.04.027. Epub 2012 Jun 28.

11.

Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring chromosomal aberrations.

Prigione A, Hossini AM, Lichtner B, Serin A, Fauler B, Megges M, Lurz R, Lehrach H, Makrantonaki E, Zouboulis CC, Adjaye J.

PLoS One. 2011;6(11):e27352. doi: 10.1371/journal.pone.0027352. Epub 2011 Nov 14.

12.

Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.

Chiu FL, Lin JT, Chuang CY, Chien T, Chen CM, Chen KH, Hsiao HY, Lin YS, Chern Y, Kuo HC.

Hum Mol Genet. 2015 Nov 1;24(21):6066-79. doi: 10.1093/hmg/ddv318. Epub 2015 Aug 11.

PMID:
26264576
13.

FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.

Liu Y, Qiao F, Leiferman PC, Ross A, Schlenker EH, Wang H.

Hum Mol Genet. 2017 Nov 15;26(22):4416-4428. doi: 10.1093/hmg/ddx327.

14.

A human iPSC model of Ligase IV deficiency reveals an important role for NHEJ-mediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors.

Tilgner K, Neganova I, Moreno-Gimeno I, Al-Aama JY, Burks D, Yung S, Singhapol C, Saretzki G, Evans J, Gorbunova V, Gennery A, Przyborski S, Stojkovic M, Armstrong L, Jeggo P, Lako M.

Cell Death Differ. 2013 Aug;20(8):1089-100. doi: 10.1038/cdd.2013.44. Epub 2013 May 31.

15.

Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity.

Tousley A, Kegel-Gleason KB.

J Huntingtons Dis. 2016 Jun 28;5(2):99-131. doi: 10.3233/JHD-160199. Review.

16.

Reprogramming Huntington monkey skin cells into pluripotent stem cells.

Chan AW, Cheng PH, Neumann A, Yang JJ.

Cell Reprogram. 2010 Oct;12(5):509-17. doi: 10.1089/cell.2010.0019.

17.

A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.

Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA.

Nature. 2009 Aug 27;460(7259):1149-53. doi: 10.1038/nature08287. Epub 2009 Aug 9.

18.

Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.

Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J.

Stem Cells. 2012 Sep;30(9):2054-62. doi: 10.1002/stem.1135. Erratum in: Stem Cells. 2012 Nov;30(11):2602.

19.

Modeling Huntington's disease with induced pluripotent stem cells.

Kaye JA, Finkbeiner S.

Mol Cell Neurosci. 2013 Sep;56:50-64. doi: 10.1016/j.mcn.2013.02.005. Epub 2013 Feb 28. Review.

20.

Chromosomal instability during neurogenesis in Huntington's disease.

Ruzo A, Croft GF, Metzger JJ, Galgoczi S, Gerber LJ, Pellegrini C, Wang H Jr, Fenner M, Tse S, Marks A, Nchako C, Brivanlou AH.

Development. 2018 Jan 29;145(2). pii: dev156844. doi: 10.1242/dev.156844.

Supplemental Content

Support Center